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Abstract 
Hypercholesterolemia impairs arteriolar dilatation, but whether the vascular abnormalities accompanying this 
condition include large artery function is unknown. We addressed this issue in 13 normotensive subjects with familial 
hypercholesterolemia (serum cholesterol 401.6 + 16.9 mg/dl, mean i SE., FHC) and no evidence of atherosclerotic 
lesions, in whom radial artery (RA) diameter and blood pressure (BP) were measured beat to beat by an echotracking 
and a Finapres device, respectively. RA compliance (RAC) was derived from the diameter/BP relationship and expressed 
over the systo-diastolic BP range, both at baseline and after a 12-min brachial artery occlusion. RAC was expressed 
also as the area under the RAC/BP curve divided for pulse BP. Measurements included maximal forearm blood flow 
(plethysmography) and minimal forearm vascular resistance (FVR) which were obtained from the values following the 
1Zmin brachial arterial occlusion. Data were collected before and after 6- and 24-month lipid lowering treatment 
(simvastatin 40 mg/day). Ten age-matched normotensive normocholesterolemic healthy subjects (N) served as controls. 
Compared to N, baseline RAC was strikingly reduced in FHC (- 53.5% P < 0.01). After ischemia RAC increased 
significantly and markedly in N (+ 38.7, P < O.Ol), while only a modest and non-significant increase was observed 
in FHC. Minimal FVR was markedly higher in FHC than in N (3.5 + 0.9 vs 1.6 f 0.1 units, P < 0.01). In FHC 
(7 subjects) RAC remained unchanged after 6 months of lipid lowering treatment, but increased markedly ( + 55.2% 
P < 0.05) when treatment was prolonged to 24 months. Lipid lowering treatment also reduced minimal FVR, the 
effect being significant both after 6 and after 24 months. No changes in RAC and minimal FVR were seen after 6 months 
in controls. Thus, in subjects with a marked increase in serum cholesterol due to FHC, not only arteriolar dilatation, 
but also RAC and distensibility are markedly impaired. This impairment can be favourably affected by an effective 
lipid lowering treatment of long duration. 
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1. Introduction 
Several studies have shown that in normoten- 
sive subjects with a high serum cholesterol con- 
centration the marked reduction in forearm 
vascular resistance (FVR) which follows pro- 
longed ischemia or intra-arterial infusion of 
acetylcholine and/or metacholine is impaired [ l- 
61. This suggests that hypercholesterolemia alters 
the ability of the arterial vessels to dilate in re- 
sponse to metabolic or pharmacologic stimuli. It 
also suggests that this alteration originates from 
interference with the secretion and/or the vascular 
effects of endothelial relaxing factors. 
No information exists as to whether the vascu- 
lar abnormality characterizing normotensive hy- 
percholesterolemic subjects also involves larger 
arteries, thereby affecting not only modulation of 
systemic vasomotor tone, but also arterial compli- 
ance. This is an important issue because a reduc- 
tion in arterial compliance increases the traumatic 
effect of blood pressure (BP) on the vessel wall 
and enhances the rate of development of 
atherosclerosis [7,8]. In the present study we ad- 
dressed this issue by measuring both forearm 
arteriolar dilatation after prolonged ischemia, 
compliance and distensibility of the radial artery 
(RA) in normotensive subjects with familial hy- 
percholesterolemia (FHC). The study was per- 
formed before and after 6 and 24 months of 
administration of a hypocholesterolemic drug to 
further examine whether the vascular abnormali- 
ties are reversible by lipid lowering treatment. 
2. Methods 
2.1. Subjects 
We investigated 23 outpatients with an age 
ranging from 45 to 53 years. Ten subjects (6 males 
and 4 females) were normocholesterolemic con- 
trols, while the remaining 13 subjects (6 males and 
7 females) had a FHC of a heterozygote type as 
indicated by (1) a plasma low-density lipoprotein 
(LDL) cholesterol concentration greater than 200 
mg/dl, (2) a plasma triglyceride concentration less 
than 110 mg/dl and (3) a serum cholesterol con- 
centration greater than 300 mg/dl, (4) a tendon or 
an eye xantoma and (5) a history of premature 
coronary heart disease in at least one first-degree 
relative [9]. The ages of the control group and of 
its male and female components were 45.4 + 2.2, 
44.3 + 3.3 and 47.0 f 3.3 years, respectively. 
The corresponding figures for the FHC group 
were 47.1 + 2.5, 46.8 + 3.7 and 47.2 + 3.6 
years. All subjects had BP values less than 140/90 
mmHg at repeated sphygmomanometric measure- 
ments. In the control group body mass index was 
23.5 + 1.5 kg/m2 and 4 subjects were smokers. 
The corresponding figures in the hypercholes- 
terolemic group were 22.5 + 0.7 and 4. No 
female subject was in menopausal status or under 
hormonal treatment. No subject had a history of 
cardiovascular disease and physical or laboratory 
evidence of cardiovascular damage (baseline and 
exercise electrocardiogram, echocardiogram, 
Holter EKG, echo-Doppler of carotid and 
femoral arteries, etc.). FHC subjects were under 
dietary and drug (a statin, a fibrate or a resin) 
treatment. Drug treatment was withdrawn 2 
months before the study. All subjects volunteered 
their participation in the study after being in- 
formed of its nature and purpose. The protocol of 
the study was approved by the Ethical Committee 
of the Institutions involved. 
2.2. Arterial compliance and distensibility 
Arterial compliance was measured in the left 
RA by an A-mode echo-tracking device (NIUS 
01, Asulab, Neuchatel, Switzerland) [lo]. The 
device consisted of a lo-MHz focalized transducer 
which was stereotaxically positioned over the RA 
2-4 cm above the wrist, direct contact with the 
skin (and arterial deformation) being prevented 
by use of a gel medium. With the subject supine 
and the left arm immobile at heart level, the 
transducer was switched to the Doppler mode and 
oriented perpendicularly to the longitudinal axis 
of the vessel. After switching to A-mode, the 
backscattered echoes from the inner anterior and 
posterior walls were visualized on an oscilloscope 
and the related radiofrequency signals were 
picked up by an electronic tracer whose displace- 
ment allowed evaluation of the vessel internal 
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diameter 300 times per s. Continuous recording of 
RA diameter was coupled with continuous 
recording of BP by a photopletysmographic 
device (Finapres, Ohmeda, Englewood, CO) posi- 
tioned on the middle finger of the ipsilateral hand 
and capable of providing BP values similar to the 
ones taken invasively from the RA and to accu- 
rately reproduce rapid and marked BP changes 
[ 11,121. The arterial diameter and BP signals were 
directed to a computer which was programmed 
(1) to provide diameter-pressure curves over the 
range of BP values obtained by the finger record- 
ing, (2) to calculate cross-sectional compliance 
based on the arctangent model of Langewouters 
et al. [13], (3) to derive compliance-pressure 
curves also over the BP range obtained by the 
finger pressure recording, and (4) to also derive 
distensibility (compliance divided by diameter)- 
pressure curve over the BP range obtained by the 
finger pressure. The echo-tracking device resolu- 
tion allowed to identify diameter changes 2 150 
pm, while the finger pressure device resolution 
allowed to identify BP changes > 2 mmHg. The 
within investigator variability of the RA diameter 
measurements, i.e. the coefficient variability of 
two measurements performed by the same opera- 
tor in two different days, was 4%. The RA diame- 
ter, RAC and BP measurements were associated 
with heart rate measurements which were ob- 
tained via the finger-pressure signal as the recipro- 
cal of the interval between consecutive systolic 
peaks. All measurements were obtained in base- 
line condition and following prolonged occlusion 
of the brachial artery (see below), a procedure 
which increases RAC thus allowing to examine its 
response to a physiological stimulus [14- 171. 
2.3. Blood flow and vascular resistance 
A venous occlusion pletysmograph (Hokanson 
Instruments, Issaquah, WA) was applied to the 
left forearm placed at the heart level, the mercury 
in sylastic strain-gauge being positioned 4-5 cm 
below the antecubital crease. Forearm blood flow 
was recorded on a polygraph (Grass Instruments, 
Quincy, MA) while circulation to the hand was 
excluded by means of a supra-systolic pressure in 
a cuff encircling the wrist. BP was measured by 
the above-mentioned finger device and FVR was 
calculated as the ratio between mean arterial pres- 
sure (diastolic BP + one third of pulse pressure) 
and forearm blood flow. All measurements were 
obtained in baseline condition and after the pro- 
longed forearm ischemia caused by occlusion of 
the brachial artery as described by Folkow et al. 
[18] (see below). This was done to obtain maximal 
dilatation and thus a minimal resistance value. 
2.4. Protocol and data analysis 
The study was conducted in the afternoon fol- 
lowing a 24-h abstinence from smoking and coffee 
consumption. The protocol of the study was as 
follows: (1) each subject was brought to the labo- 
ratory, placed in the supine position and fitted 
with the BP measuring and the echo-tracking 
device, (2) after a 20-min interval, BP, heart rate, 
diameter-pressure curves and compliance-pressure 
curves were measured continuously for 15 min, (3) 
a suprasystolic pressure was applied for 12 min to 
the left arm to occlude the brachial artery and all 
hemodynamic measurements mentioned above 
were obtained again during the 5 min which fol- 
lowed the release of the occlusion [14-171; the 
measurements were started 30 s after the actual 
release to allow autocalibration of the finger pres- 
sure device [11,12], (4) the echo-tracking and 
finger BP devices were removed and the left fore- 
arm was fitted with the venous occlusion plethys- 
mography, the BP measuring device being now 
positioned on the middle finger of the right arm, 
(5) following a 20-min interval forearm blood 
flow, BP and heart rate were measured for 15 
min, (6) a suprasystolic pressure was applied for 
12 min to the left arm to occlude the brachial 
artery and in the last 2 min of the occlusion 
period the subjects were asked to rhythmically 
clench and relax the left hand, (7) forearm blood 
flow, BP and heart rate were again measured 
during the 5 min which followed the release of the 
occlusion, (8) the 13 familial hypercholesterolemic 
subjects were maintained on a low lipid diet and 
given simvastatin at a dose of 40 mg once daily. 
Only 7 (4 males and 3 females, age 46.1 + 3.0 
years) of these 13 patients agreed to participate to 
a 2nd evaluation after a 6 month treatment, (9) in 
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the same 7 subjects a third study was carried out 
after 24 months of dietary and simvastatin treat- 
ment. Seven subjects (4 males and 3 females, age 
45.6 + 2.7 years) from the control group were 
also studied again after a 6-month period. 
RA diameter, compliance and distensibility val- 
ues were always averaged over consecutive peri- 
ods of 4 s. Baseline diameter-pressure, 
compliance-pressure and distensibility-pressure 
curves were obtained by averaging 5 periods of 4 
s taken at 3-min intervals during the 15-min peri- 
ods indicated at (2) (see above). Post-ischemic 
diameter-pressure, compliance-pressure and dis- 
tensibility-pressure curves were obtained by tak- 
ing the 4-s period showing the maximal increase 
in diameter following the release of brachial 
artery occlusion. Baseline blood flow was ob- 
tained by averaging 5 consecutive values over the 
2.5 min preceeding brachial artery occlusion while 
post-ischemic forearm blood flow was obtained by 
taking the single maximal blood flow within the 
minute following the release of brachial artery 
occlusion. BP, heart rate and FVR were calcu- 
lated at corresponding times. Total serum choles- 
terol, LDL cholesterol, high-density lipoprotein 
(HDL) cholesterol and triglycerides were mea- 
sured from a blood sample taken from an antecu- 
bital vein in the morning preceeding the study. In 
familial hypercholesterolemic subjects lipid profile 
was also determined before wash-out from dietary 
and drug treatment. 
Data from individual subjects were averaged 
and expressed as mean + S.E.M. for each group. 
The statistical significance of the differences in the 
means was assessed by the two-way analysis of 
variance. The two-tailed t-test for paired or un- 
paired observations was used to locate differences 
between the various conditions and the two 
groups, respectively. RA diameter was compared 
at the value corresponding to diastolic BP. To 
statistically compare RAC and distensibility, cal- 
culations were made of the integral of the area 
under the curve relating compliance and distensi- 
bility to the arterial BP normalized for the BP 
range from diastole to systole to take into account 
between-subject differences in pulse pressure value 
[14]. This was referred to as ‘compliance index’ 
and ‘distensibility index’. A P value < 0.05 was 
taken as the level of statistical significance. 
Throughout the study the symbol + refers to the 
standard error of the mean. 
3. Results 
3.1. Baseline BP, heart rate and lipid profile 
Table 1 shows that normocholesterolemic con- 
trols and familial hypercholesterolemic subjects 
had similar BP and heart rate values. Compared 
to control subjects total serum and LDL choles- 
terol were elevated in familial hypercholes- 
terolemic subjects before wash-out from drug 
treatment, a further small although significant 
increase being observed after wash-out from drug 
treatment. HDL cholesterol and triglycerides were 
similar in the control and familial hypercholes- 
terolemic groups, both before and after wash-out 
from drug therapy. 
Table 1 
Hemodynamic and lipid profile values in normocholes- 
terolemic (C) and familial hypercholesterolemic subjects 
W-W 
Variable c (n = 10) FHC (n = 13) 
Before 
wash-out 
After 
wash-out 
SBP (mmHg) 115.2 + 7.3 # 106.5 + 4.8 
DBP (mmHg) 68.9 + 4.9 # 60.0 k 3.2 
HR (bjmin) 66.3 k 4.9 # 16.3 + 3.0 
Serum 212.1 + 6.4 388.2 k 401.6 + 
cholesterol 15.6* 16.9*,** 
(mg/dU 
LDL 135.1 * 4.8 309.5 * 331.7 j; 
cholesterol 16.2* 17 1* ** . , 
@g/d0 
HDL 55.2 _+ 4.2 53.8 f 51.8 It. 5.9 
cholesterol 5.2 
(w/W 
Triglycerides 108.5 k 18.5 123.4 k 109.5 _+ 8.9 
(mg/dU 14.2 
SBP, systolic blood pressure; DBP, diastolic blood pressure; 
HR, heart rate. 
Data are expressed as means k S.E.M. *P < 0.01 vs. N; **P 
< 0.01 vs. FHC before wash-out. 
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Fig. 1. Baseline radial artery diameter, compliance and distensibility in normocholesterolemic subjects C (n = 10) (C/ 0) and in 
subjects with FHC (n = 13) (A/m). In the upper panels values are shown over the systo-diastolic blood pressure range. In the 
lower panels diameter is shown at diastolic blood pressure only while compliance and distensibility are shown as compliance index 
and distensibility index (see Methods). Data are shown as means + S.E.M.; *P < 0.05. 
3.2. RAC and distensibility 
As shown in Fig. 1, upper panels, in both 
control subjects and familial hypercholesterolemic 
subjects, an increase in BP from diastolic to sys- 
tolic values was associated with a small progres- 
sive increase in RA diameter and a marked and 
progressive reduction in RAC and distensibility. 
RA diameter was slightly less in familial hyperc- 
holesterolemic subjects than in controls, although 
the difference at diastolic BP was not statistically 
significant (Fig. 1, lower left panel). In contrast, in 
familial hypercholesterolemics RAC and distensi- 
bility were strikingly reduced as compared to con- 
trols, the reduction being evident throughout the 
systo-diastolic pressure range. The compliance 
and distensibility indexes were less than half in the 
familial hypercholesterolemic than in the control 
group (Fig. 1, right panels). 
Fig. 2 shows that in control subjects RA diame- 
ter, compliance and distensibility increased 
markedly after release from forearm ischemia 
throughout the systo-diastolic pressure range. In 
contrast, RA diameter, compliance and distensi- 
bility showed a smaller and non-significant in- 
crease in familial hypercholesterolemic subjects. 
In both groups BP was not affected by forearm 
ischemia. 
3.3. Maximal forearm uasodilatation 
Fig. 3 shows that in control and familial hyper- 
cholesterolemic subjects baseline forearm blood 
flow and vascular resistance were similar. In con- 
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Fig. 2. Radial artery diameter, compliance and distensibility-pressure curves before (pre-ischemia) and after release from ischemia 
in the two groups of subjects of Fig. 1. Data are shown as means k S.E.M. (post-ischemia). Other explanations as in Fig. 1. 
trol subjects release from prolonged forearm is- 
chemia was associated with a marked increase in 
forearm blood flow and a marked reduction in 
FVR, whereas in familial hypercholesterolemic 
subjects both the increase in blood flow and the 
reduction in vascular resistance were much less 
pronounced. As a result, minimal FVR was much 
greater in the familial hypercholesterolemic than 
in the control group. 
3.4. Lipid lowering treatment 
As shown in Table 2 in control subjects BP, 
heart rate and lipid profile were similar in the two 
studies performed over a 6-month interval. In 
familial hypercholesterolemic subjects BP and 
heart rate were similar before and after 6- and 
24-month lipid lowering drug treatment. Total 
serum cholesterol and LDL cholesterol were 
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Fig. 3. Forearm blood flow and vascular resistance in the two groups of subjects of Fig. 1. Data (means k S.E.M.) are shown at 
baseline condition and during the vasodilatation occurring after the release from ischemia. 
clearly reduced by lipid lowering treatment after 
6 months and the reduction was even more pro- 
nounced after 24 months. Both after 6 and after 
24 month lipid lowering treatment caused a small 
and non-significant increase of HDL cholesterol 
leaving triglycerides unaffected. 
The effects of lipid lowering treatment on max- 
imal forearm blood flow and minimal FVR are 
shown in Fig. 4. In control subjects maximal 
forearm blood and minimal FVR were not sig- 
nificantly different in the two studies performed 
over a 6-month interval. In familial hypercholes- 
terolemic subjects maximal forearm blood flow 
was significantly increased and minimal FVR 
was significantly reduced after 6 months of lipid 
lowering treatment and the reduction became 
even more pronounced when treatment was pro- 
longed to 24 months. As shown in Fig. 4 (lower 
panels) and in Fig. 5 (upper panels) in control 
subjects RAC and distensibility pressure curves 
and indexes were similar in the two studies per- 
formed over the 6-month interval. Pre-ischemic 
RAC and distensibility were not significantly al- 
tered by 6 months of lipid lowering treatment 
also in familial hypercholesterolemic subjects. Af- 
ter 24 months of lipid lowering treatment, how- 
ever, pre-ischemic compliance and distensibility 
values were increased, the difference in compli- 
ance and distensibility indexes being statistically 
significant. Post-ischemic compliance and disten- 
sibility values were slightly increased by the 6- 
and 24-month lipid lowering treatment but the 
changes were less evident and not statistically 
significant (Fig. 4, lower panels and Fig. 5, lower 
panels). There was never a significant correlation 
between blood flow, compliance and distensibility 
values either before or after ischemia (r never 
> 0.39). 
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Table 2 
Hemodynamics and lipid profile in normocholesterolemic controls (C) studied before and after 6 months and in subjects with FHC 
studied before and after 6 and 24 months of lipid lowering treatment 
Variable c (n = 7) FHC (n = 7) 
First study After 6 months First study Treatment 6 months Treatment 24 months 
SBP (mmHg) 
DBP (mmHg) 
HR (b/min) 
Serum cholesterol 
Ow/dl) 
111.0 f 9.9 118.0 f 5.3 100.8 k 6.5 108.3 k 5.8 111.7 + 11.1 
65.8 k 5.1 71.0 + 2.7 55.8 k 3.2 61.8 fr 3.8 61.6 & 8.5 
64.0 * 5.9 65.0 f 4.1 72.1 & 3.1 68.3 L- 3.0 72.8 k 2.8 
217.1 f 5.9 220.0 & 6.7 418.4 + 27.5’ 341.0 f 33.3*,** 279.1 + 14.5*,**,*** 
LDL cholesterol 
Ox/W 
HDL cholesterol 
Ow/dl) 
Triglycerides (mg/dl) 
139.8 + 5.1 129.0 * 9.2 357.8 + 25.2* 271.0 + 30.1*,** 199.7 j, 20.1*,**,*** 
57.0 + 5.7 58.0 + 5.7 45.4 * 3.7 46.7 + 2.5 55.7 + 5.0 
98.5 i- 11.7 93.7 + 12.1 111.3 + 7.8 125.7 rt 17.3 96.2 + 20.0 
Data are expressed as means rfr S.E.M. Symbols and abbreviations as in Table 1. *P < 0.01 vs. N; **P < 0.01 vs. first study, 
***vs. 6 months treatment (FHC). 
4. Discussion 
Our results show that the marked elevation in 
serum cholesterol which characterizes FHC is ac- 
companied by a marked reduction in the ability of 
forearm arterioles to maximally dilate following 
prolonged ischemia. They further show that this 
reduction is associated with a marked reduction in 
RAC and distensibility which become also unable 
to increase after prolonged ischemia, at variance 
from the pronounced increase seen in normoc- 
holesterolemic individuals. This allows to con- 
clude that FHC is characterized by a striking 
impairment of resistance vessel dilatation. It is 
also characterized, however, by a striking impair- 
ment of the main function of arteries of greater 
caliber, i.e. by a reduction and a loss of modula- 
tion of arterial compliance and distensibility. 
We can speculate that this alteration is caused 
by a reduction of arterial blood flow which re- 
duces endothelial shear stress and thus secretion 
of endothelial factors increasing vessel wall com- 
pliance and distensibility via smooth muscle relax- 
ation WI. However, in familial 
hypercholesterolemic subjects baseline RAC and 
distensibility were strikingly reduced whereas 
baseline forearm blood flow was superimposable 
to that of control subjects. Furthermore, during 
the follow-up period the change in post-ischemic 
or maximal forearm blood flow did not proceed in 
parallel with the change in post-ischemic arterial 
compliance and distensibility. Neither in baseline 
condition nor after ischemia did the two sets of 
values show a significant correlation. This sug- 
gests that the reduction of RAC and distensibility 
of familial hypercholesterolemic subjects is at least 
in part due to abnormalities of the wall of this 
conduit vessel which is independent of the vessel 
diameter (reduction in distensibility) and thus in- 
trinsic in nature. Three possibilities can be sug- 
gested. Firstly, in FHC there is an impaired 
secretion and/or function of endothelial relaxing 
factors independent of the flow regimen [19]. Sec- 
ondly, the vessel wall is structurally altered by an 
increased deposition of cholesterol (a ‘pre- 
atherosclerotic change’) leading to an increased 
wall stiffness [20,21]. Thirdly, in this condition an 
increased concentration of oxidized lipoproteins 
[22] has a toxic vascular effect [23-261 that im- 
pairs arterial function. 
Creager et al. [l], Chowienczyk et al. [2] and 
Casino et al. [3] have shown that in normotensive 
subjects with an average serum cholesterol of 275 
mg/dl, 300 mg/dl and 292 mg/dl, respectively, the 
forearm dilatation induced by intra-arterial infu- 
sion of acetyl- or meta-choline was less than that 
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Fig. 4. Forearm blood flow, minimal vascular resistance and radial artery compliance index at baseline and after ischemia in FHC 
studied before (1st study) and after 6 and 24 months of lipid lowering treatment (T, 6 months; T, 24 months). Data from control 
(C) subjects studied twice at a &month interval are also shown. Mean +_ S.E.M. Symbols as in preceeding figures. 
seen in normotensive normocholesterolemic con- 
trols, whereas the forearm vasodilatation induced 
by intra-arterial infusion of nitroprusside was sim- 
ilar in the two groups. This led to the conclusion 
that in hypercholesterolemia of a moderate degree 
the arteriolar modulation exerted by endothelial 
relaxing factors, whose secretion is promoted by 
acetyl- and meta-choline, is impaired, while the 
arteriolar modulation independent from these fac- 
tors is normal [l-3]. Our study provides addi- 
tional evidence on this issue because in our 
familial hypercholesterolemic subjects, in whom 
serum cholesterol was 401 mg/dl, prolonged is- 
chemia caused an arteriolar dilatation that was 
strikingly less than the one seen in control normo- 
cholesterolemic subjects. Because post-ischemic 
arteriolar dilatation is regarded as a ‘non-en- 
dothelial’ phenomenon (like the dilatation in- 
duced by nitroprussiate) [27], we suggest that 
while a moderate increase in serum cholesterol 
adversely affects the endothelial modulation of 
arteriolar tone only, a more marked increase in 
serum cholesterol impairs the overall ability of 
arterioles to dilate in a non-selective fashion. We 
also suggest that this is the case for the main 
function of larger arteries, i.e. compliance, whose 
marked post-ischemic increase was strikingly less 
in familial hypercholesterolemic subjects. An al- 
ternative possibility is that a non-selective and 
more marked loss of arteriolar dilatation and of 
arterial compliance increase is due to specific fea- 
tures of FHC affecting vascular wall properties, 
that are unrelated to serum cholesterol levels. 
However, this possibility is not supported by the 
evidence of a reversal of the arterial and arteriolar 
alterations induced by lipid lowering treatment. 
In familial hypercholesterolemic subjects a 6- 
month treatment with simvastatin, that caused a 
15.9 and 21.0% reduction in total and LDL 
cholesterol respectively, was accompanied by an 
FAYUAL WPERCHOLESlEROLEU(A (n = 7) 
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Fig. 5. Radial artery compliance and distensibility-pressure curves before and after ischemia in the subjects of Fig. 4. Symbols as 
in Fig. 4. 
improvement in post-ischemic or maximal dilata- 
tion of forearm arterioles whereas baseline RAC 
increased in only a slight and non-significant fash- 
ion. However, when lipid lowering treatment was 
prolonged to 24 months and total and LDL 
cholesterol reduction was greater (20.7 and 40.9% 
respectively), the improvement in maximal dilata- 
tion of forearm arterioles was slightly more pro- 
nounced, but a significant and clearcut increase in 
baseline RAC was observed as well. This allows 
to conclude that the marked alteration in arterio- 
lar and arterial function seen in FHC is reversible 
by lipid lowering treatment. This goal, however, 
can be achieved if the reduction in total and LDL 
cholesterol is marked and long-lasting. This ap- 
pears to be crucial particularly for the reversibility 
of the abnormality in RAC. 
Our data are in line with the beneficial results 
on progression of atherosclerosis observed by nor- 
malizing lipid profile by means of a variety of 
lipid lowering interventions in subjects with FHC 
with a marked alteration in lipid profile [28-321. 
They add to these results, however, the finding 
that the benefit extends to the basic functions of 
the arterial vessels, i.e. to the ability of the arteri- 
ole to dilate and of the larger artery to distend in 
response to physiological stimuli. Since lipid low- 
ering treatment reduced minimal FVR already 
after 6 months, whereas the improvement in RAC 
was observed only after 24 months, in subjects 
with FHC, reversal of the arteriolar impairment 
may be faster than reversal of the larger artery 
one. Twenty-four months of lipid lowering treat- 
ment did not significantly improve post-ischemic 
RAC. Thus, in FHC it may be more difficult or it 
may take longer to restore post-ischemic than 
baseline compliance values, suggesting that a re- 
duced RAC reserve may thus remain a sign of an 
impaired compliance even during a long-term 
effective lipid lowering treatment. Our study does 
not answer the question whether in FHC large 
arteries with a predominant elastic structure share 
the striking reduction in compliance shown by the 
more muscular arteries such as the radial one. 
Studying large arteries compliance in FHC may 
pose special difficulties, however, because dynamic 
evaluation of compliance over the systo-diastolic 
pressure range is not yet possible in the aorta and 
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other large arteries. Furthermore, at variance 
from the RA [33], large elastic arteries frequently 
undergo early atherosclerotic hanges [34,35], i.e. 
they frequently undergo non-specific structural 
damage which may superimpose on and thus pre- 
vent identification of more specific effects of FHC 
on arterial compliance [36,37]. 
Our results have clinical implications. An im- 
paired arteriolar dilatation implies a potential 
danger for organs, such as the heart, which meet 
an increased metabolic requirement with an in- 
crease in blood flow, and indeed a reduced coro- 
nary reserve has been shown in normotensive 
subjects with a marked elevation in serum choles- 
terol [38-401. Furthermore, an increased arterial 
stiffness may on the one hand reduce coronary 
blood flow during diastole and on the other hand 
increase aortic impedance, thereby offsetting the 
ratio between oxygen supply and demand of the 
heart [41]. An increased arterial stiffness may also 
increase the traumatic effect of BP on the arterial 
wall and thus favour the development of 
atherosclerosis. In animals this is exemplified by 
the diffuse atheromatic lesions displayed by 
carotid arteries in which stiffness is markedly in- 
creased by encasting vessels within rigid chambers 
[8]. Finally, even in subjects characterized by a 
marked alteration in lipid profile such as the 
familial hypercholesterolemic ones, treatment by 
lipid lowering drugs may reverse these arterial and 
arteriolar effects, thereby preventing the adverse 
consequences. To achieve this purpose, however, 
treatment must. be effective over a long period. 
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